Focus Partners Wealth
CMPX icon

Focus Partners Wealth’s Compass Therapeutics CMPX Stock Holding History

Focus Partners Wealth’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.6K Sell
14,292
-4,303
-23% -$24.8K ﹤0.01% 2544
2025
Q4 		$99.9K Buy
18,595
+2,790
+18% +$12.9K ﹤0.01% 2554
2025
Q3 		$56K Buy
15,805
+2,206
+16% +$6.97K ﹤0.01% 2157
2025
Q2 		$35.4K Sell
13,599
-2
-0% -$4 ﹤0.01% 1986
2025
Q1 		$25.8K Buy
13,601
+10
+0.1% +$27 ﹤0.01% 1864
2024
Q4 		$19.7K Buy
+13,591
New +$22.6K ﹤0.01% 1848

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Focus Partners Wealth's CMPX Position: Q1 2026 in Review

Focus Partners Wealth reduced its Compass Therapeutics (CMPX) stake by 23% in Q1 2026, selling an estimated $24.8K and leaving 14,292 shares worth $75.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2544.

Focus Partners Wealth first reported a position in CMPX in Q4 2024 and has held it in 6 quarters since. The position peaked at $99.9K in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Focus Partners Wealth held 14,292 shares of Compass Therapeutics worth $75.6K as of Q1 2026.
  • Focus Partners Wealth sold 4,303 Compass Therapeutics shares in Q1 2026, an estimated $24.8K.
  • Compass Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2544 holding.
  • Focus Partners Wealth first reported a position in Compass Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Focus Partners Wealth's Compass Therapeutics position peaked at $99.9K in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.